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Abstract
Background: The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared
to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with
predominantly non-squamous histology in the Spanish healthcare setting.
Methods: A Markov model was designed consisting of stable, responsive, progressive disease and death states.
Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based
on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for
non-squamous patients treated with pemetrexed compared with docetaxel. Costs were collected from the Spanish
healthcare perspective.
Results: Outcomes of the model included total costs, total quality-adjusted life years (QALYs), total life years gained
(LYG) and total progression-free survival (PFS). Mean survival was 1.03 years for the pemetrexed arm and 0.89 years
in the docetaxel arm; QALYs were 0.52 compared to 0.42. Per-patient lifetime costs were € 34677 and € 32343,
respectively. Incremental cost-effectiveness ratios were € 23967 per QALY gained and € 17225 per LYG.
Conclusions: Pemetrexed as a second-line treatment option for patients with a predominantly non-squamous
histology in NSCLC is a cost-effective alternative to docetaxel according to the € 30000/QALY threshold commonly
accepted in Spain.
Background
Lung cancer is the leading cause of cancer deaths world-
wide [1]. It is the most common tumour in Spain, found
mainly in men, and has the highest mortality. In 2001,
there were over 16000 cases of lung cancer diagnosed in
men and 1900 cases in women [2].
In 2005, 16647 men and 2471 women died from lung
cancer, accounting for 27% and 7%, respectively, of all
cancer deaths in Spain [3]. In Spain median survival
rates of 40 weeks have been reported for patients with
non-small cell lung cancer (NSCLC) [4] and 5-year sur-
vival is poor, estimated at only around 7% to 12% [2].
In advanced-stage NSCLC, doublet combinations of
platinum compounds are reference regimens for first-
line treatment, with approximately a third of patients
obtaining an objective response and another 20% to 30%
achieving temporary disease stabilization. After failure of
first-line chemotherapy, many patients still have a good
performance status and remain candidates to receive
further anti-tumour treatment. Two chemotherapeutic
agents, docetaxel and pemetrexed, and the biologic drug
erlotinib are currently approved for clinical use in the
second-line setting, but specifically, a single-agent che-
motherapy using docetaxel or pemetrexed is the recom-
mended first option for these patients [5].
Docetaxel is currently one of the most commonly
used treatments for patients who have progressed after
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shown superior efficacy compared to a number of other
regimens and best supportive care (BSC) alone [6,7].
Pemetrexed is a pyrrolopyrimidine-based antifolate
cytotoxic drug traditionally used as monotherapy for the
second-line treatment of patients with locally advanced
or metastatic NSCLC and, in combination with cisplatin,
for the treatment of chemonaïve patients with unresect-
able malignant pleural mesothelioma (MPM). Recently
presented data that showed a treatment-by-histology
interaction associated with different clinical outcomes
has resulted in a change in the NSCLC indication to
patients with other than predominantly squamous cell
histology. Moreover, the Summary of Product Charac-
teristics (SmPC) of Alimta was extended in April 2008
to include first-line treatment of NSCLC in combination
with cisplatin, also in the other than predominantly
squamous cell histology group [8].
The clinical benefit of pemetrexed treatment in
patients with advanced predominantly non-squamous
NSCLC has been consistently demonstrated across three
randomized phase III trials. A pre-specified analysis of a
first-line study comparing pemetrexed and cisplatin with
gemcitabine and cisplatin in NSCLC reported improved
overall survival in pemetrexed-treated patients with
non-squamous histology compared with those with
squamous cell histology [9]. This outcome advantage of
pemetrexed in non-squamous histology was confirmed
by a retrospective unplanned subgroup analysis of a
phase III trial comparing second-line pemetrexed versus
docetaxel [10] and by a pre-planned analysis of a phase
III trial of platinum-based chemotherapy in the first-line
setting, followed or not by pemetrexed maintenance
[11]. The efficacy differences that were found, relative to
histology type, may give clinicians clues for refining
treatment choices and finally achieve the goal of indivi-
dualised drug therapy for patients with NSCLC.
In the current context of increasingly stretched health-
care budgets, however, efficacy and safety data should
not be used as the only criteria to guide therapeutic
decisions. The growing needs and demands of the popu-
lation, leading to increasing use of cancer drugs, and the
higher costs of new treatments have forced decision-
makers to place greater emphasis on how to use the
limited resources in the most efficient way. The eco-
nomic evaluation of health interventions can assist local
or national budget-holders in their resource allocation
decisions. It can also provide guidance for medical
oncologists by confirming patient subgroups for which
pemetrexed may be not only cost-effective, but also
have clinically superior outcomes. The aim of our study
was to conduct an economic evaluation of pemetrexed
versus docetaxel in the second-line treatment of patients
with predominantly non-squamous NSCLC based on
the findings of the Scagliotti retrospective analysis, as
one step forward in the “tailored therapy” approach.
Methods
Model Structure
The economic model was built in MS Excel
© and fol-
lows a Markov structure based on three main health
states: stable, response and progression. A schematic of
the model is shown in Figure 1. The chronology of the
model may be split roughly into the treatment phase
and the post treatment phase, although patients who
enter Progression will discontinue their treatment
immediately, while other patients may complete their
full course of chemotherapy. This means that some
overlap of the two phases exists among the patient
cohort. The cycle length is 21 days, and for each
model cycle patients face a risk of changing health
states to Response, Progression or Death, and also of
experiencing a treatment-related adverse event (AE).
Patients are permitted up to a maximum of 6 cycles of
chemotherapy, after which they will either enter the
post treatment states of Stable or Response until they
enter Progression. Patients who progress during che-
motherapy may also discontinue prior to treatment
completion and proceed directly to the Progressive
state. Stable and responding patients can either move
to Progression or remain in the current state. The
model assumes death follows Progression. Patients who
have responded and then progress move directly to the
Progression state from the Response state. Disconti-
nuation occurs when patients stop chemotherapy treat-
m e n t .I ti sa s s u m e dt h a ts u c hp a t i e n t sp r o c e e dd i r e c t l y
to the Progressive state.
In both the Response and Stable states patients have
ap r o b a b i l i t yo fd e v e l o p i n gA E sa sl o n ga st h e ya r ei n
the treatment phase. These AEs include febrile neutro-
penia (FN), neutropenia, nausea/vomiting, fatigue, diar-
rhoea, rash and alopecia (hair loss). FN is the only
adverse event to carry a risk of death. Discontinuations
d u et oA E sa r ec o n s i d e r e da n dt h o s ew h os t o pa c t i v e
treatment are immediately assumed to progress in their
disease.
The study takes the perspective of the Spanish Health
Care system focusing on direct medical costs (che-
motherapy treatment, AE treatment and BSC). The key
comparators for the model are pemetrexed (Alimta®)
and docetaxel (Taxotere®).
Model Parameters
The patient population under evaluation in this model
were stage IIIB or IV patients with NSCLC with predo-
minantly non-squamous histology who had previously
undergone a course of chemotherapy and were eligible
for second-line therapy. The time horizon was set to
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lifetime model and was confirmed by Spanish clinicians
as a suitable timeframe. Discount rates were set to 3%
for both costs and benefits to account for the time pre-
ference of costs and benefits accrued.
Model Inputs: Efficacy
All clinical inputs for the predominantly non-squamous
population come from the post-hoc retrospective sub-
group analysis of the head-to-head JMEI trial [10] [data
on file, Eli Lilly JMEI trial 2008], which compared sec-
ond-line pemetrexed versus docetaxel. This retrospective
analysis was the source on which the European Medi-
cines Agency (EMEA) based its decision to change the
SmPC indication. Several other randomized trials have
reinforced this finding of improved survival in the pre-
dominantly non-squamous group including first-line
and maintenance therapies [9-11]. The model input
variables are efficacy (overall survival, progression-free
survival and tumour response), AE rates and AE
discontinuations.
Median overall survival was used to determine the risk
of death in the progression state. Median overall survival
from the trial was chosen as more appropriate than
mean values, as mean values would be skewed and rely
on assumptions of the survival of those who did not fail
during the course of follow-up. The median progres-
sion-free survival (PFS) duration was subtracted from
the median overall survival duration in order to estimate
the median time spent in progression before death. In
order to calculate a risk of dying, an exponential distri-
bution was assumed with a constant risk of death,
derived from the formula ln(2)/(median time in progres-
sion). This risk of death was adjusted to fit a 3-week
period, corresponding to the per-cycle risk of death.
The exponential distribution is often used for the mod-
elling of failure times and is applicable for use in time-
to-event data [12].
PFS was defined as the time from randomization
until documented progression or death from any cause
and was censored at the date of the last follow-up visit
for patients who were still alive and who had not pro-
gressed. The PFS data were split out into responders
and non-responders to account for the difference in
PFS duration achieved by those two groups. Tumour
response was assessed using the Southwest Oncology
Group criteria and required confirmation at least 4
weeks after initial response. The efficacy inputs are
summarised in Table 1. Overall survival for patients
with non-squamous NSCLC treated with pemetrexed
Figure 1 Model schematic. Diagrammatic view of the model structure comprising three main health states: Stable, Response and Progression.
(FN: febrile neutropenia; AE: adverse event)
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9.3 vs. 8.0 months; HR 0.778, 95% CI 0.607-0.997).
Model Inputs: Adverse Events (AEs)
The most common (> 5%) Grade 3/4 drug-related AEs
experienced by patients with NSCLC of non-squamous
histology reported in the JMEI study were included in
the model. Grades 1/2 drug-related AEs, apart from alo-
pecia, were excluded on the basis that they do not have a
major impact on patients’ q u a l i t yo fl i f ea n dc o s t so f
treatment. FN was included even if it only occurred in a
s m a l ln u m b e ro fp a t i e n t sa si ti st h eo n l yA Ew i t har i s k
of mortality and has significant cost implications. AEs
were assumed to be mutually exclusive of one another:
very few patients experienced more than one grade 3/4
AE concurrently. The incidences of nausea and vomiting
were added to yield a single AE input. It was assumed for
all AEs, except alopecia, that they were resolved/treated
in the same cycle within which they occurred and the uti-
lity decrement was linked to a single cycle duration. For
all AEs except FN, a constant risk was assumed.
With respect to FN, it was assumed that most cases
would occur after administration of the first cycle of
treatment and thereafter, a constant risk (per cycle) was
assumed: the FN risk was varied over the Cycles 1, 2
and Cycles 3 and above, and remained constant for each
cycle after cycle 3 (Table 2). A mortality risk of 3.9%
was set based on mean all-cause mortality data taken
from a review of 23 studies on FN covering 4938
patients [13]. One hundred percent of patients are
assumed to be hospitalised for grade 3/4 FN.
The AE rates are shown in Table 3. A significantly
higher number of patients in the docetaxel group
experienced haematological toxicities such as FN and
neutropenia, compared to those in the pemetrexed
group. Patients receiving pemetrexed also reported a
lower incidence of patient-felt toxicities, like alopecia.
These rates are comparable with the AEs reported in
the overall NSCLC population in the JMEI study.
Treatment discontinuatio n sd u et os e r i o u sA E sa n d
discontinuations due to patients’ wishes were incorpo-
rated into the model, these being the two main reasons
for stopping treatment. Discontinuation rates for peme-
trexed were 7.42% due to serious AEs and 8.68% due to
patients’ wishes.
Model Inputs: Costs
Costs included in the model were those related to che-
motherapy treatment, AE treatment and BSC (Table 4).
The Spanish reference database BOT issued by the Gen-
eral Spanish Council of Pharmacists [14] was used for
medication prices, including chemotherapy. Public prices
were applied and value-added tax (VAT) included. Hos-
pital treatment costs and laboratory tests were sourced
from the most up-to-date references from the healthcare
databases Oblikue and SOIKOS [15,16] and expressed in
year 2007 values, inflating earlier values where necessary
by using published consumer price indices reported by
the Spanish National Statistics Institute [17].
The remaining costs for this model were obtained
from two sources. The first was an independent opi-
nion-based study by IMS Health Economics and Out-
comes Research (HEOR) Spain [Unit Cost and Patterns
of Treatment of Adverse Events and Providing Best Sup-
portive care in patients with Stages IIIb and IV Non-
Small Cell Lung Cancer. A report from Opinion-Based
Survey for Spain. IMS Health, 2008] conducted among
an expert panel of 5 oncologists in Spain using a semi-
structured questionnaire to describe the local treatment
practice and collect data on costs of treatment in
NSCLC. The second report is a cost data collection
Table 1 Clinical efficacy inputs
All patients with non-squamous histology PEM
N = 205
DOC
N = 194
Median survival, months
1 (95% CI) 9.30 (7.80-9.7) 8.00 (6.30-9.30)
Overall survival hazard ratio (95% CI)
1 0.78 (0.61-1.00)
Median PFS, months
1 3.10 3.00
PFS hazard ratio (95% CI)
1 0.82 (0.66-1.02)
Response rates (%) (Complete response + partial response)
2 10.78 8.81
Response rates (95% CI) (7.25-15.80) (5.59-13.66)
Proportion of responders by cycle 2 (%)
3 45.83
Source:
1 Scagliotti et al, 2009 [10];
2 Data on file, Eli Lilly, 2008;
3 Taken from JMEI data, number of responders by cycle 2/total responders (22/48)
PEM: pemetrexed; DOC: docetaxel; CI: confidential interval; PFS: progression-free survival
Table 1 presents the clinical efficacy inputs that drive the model.
Table 2 Risk of febrile neutropenia across the cycles
Risk of febrile neutropenia Cycle 1 Cycle 2 Cycle 3+
Risk per cycle with pemetrexed 0.00% 1.55% 1.04%
Risk per cycle with docetaxel 12.11% 2.63% 1.05%
Source: Eli Lilly, data on file, JMEI trial, 2008
The risk per cycle of a patient experiencing FN assuming greatest risk after
cycle 1, remaining constant after cycle 3.
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BSC costs in patients with advanced NSCLC [Cost of
treatment for 1st line non-small cell lung cancer
(NSCLC) in Europe. Report on Spain. IMS Health, 2007]
Model Inputs: Chemotherapy Related Costs
Pre-medication and laboratory tests were based on the
SmPC and Spanish clinical practice for both peme-
trexed and docetaxel. In line with the SmPC for peme-
trexed, patients were required to take oral folic acid,
intramuscular vitamin B12 injection and corticosteroid
treatment before, during and after treatment with
pemetrexed. Docetaxel patients received only corticos-
teroid treatment. Laboratory tests comprised full blood
count with white cell differential, liver function tests
and renal function tests applied as per the individual
SmPCs.
Chemotherapy unit costs were calculated using a point
estimate body surface area of 1.7 m
2.R e s o u r c eu s ef o r
each administration session was a cost of € 135.21 based
on less than 2 hours clinic time for administering the
chemotherapy [16].
Model Inputs: Adverse Events Costs
Bottom-up cost data for AEs was not available from
published sources. An opinion-based survey conducted
among five oncologists in Spain provided information
on the treatment algorithms and resource use for each
of the grade 3/4 AEs, based on hospitalisation and drug
costs. The estimated AE cost is a weighted average of
AE costs in four settings: inpatient including hospitaliza-
tion costs, outpatient, daycare and no treatment; the dis-
tribution of patients across these settings was provided
by the clinicians.
Table 3 Incidence of Grade 3/4 adverse events
FN Neutropenia Nausea/Vomiting Fatigue Diarrhoea Alopecia
Pemetrexed 2.59% 4.66% 1.55% 5.70% 0.52% 7.25%
Docetaxel 15.79% 41.58% 1.58% 5.79% 1.58% 38.95%
Source: Eli Lilly, data on file, JMEI trial, 2008
FN: febrile neutropenia
Adverse events for the most common Grade 3/4 rates from the predominantly non-squamous population from the JMEI trial, 2008.
Table 4 Unit costs
Resource Price (€) Source
Dexamethasone 1 mg tablets × 30 (Fortecortin®) 2.97 [14]
Folic Acid 400 mcg tablets × 28 (Zolico®) 3.39
Vitamin B12 1 mg vial × 8 (Cromatonbic®) 3.12
Pemetrexed (100 mg vial) 297.35
Pemetrexed (500 mg vial) 1295.75
Docetaxel (20 mg vial) 190.09
Docetaxel (80 mg vial) 604.43
Complete Blood Count includes white cell differential 16.05 [16]
Biochemical Analysis includes renal function and liver function tests 24.78
Chemotherapy administration < 2 hours clinic time 135.21 [16]
Neutropenia 2086.13 Expert panel, [18]
Nausea and Vomiting 516.20
Fatigue 575.30
Diarrhoea 691.04
Alopecia (Hair loss) 0.00
Rash 64.74
Febrile Neutropenia 3310.85
BSC costs Expert panel
Cost of weighted home visit per 21 day cycle 125.83
Cost of weighted outpatient visit per 21 day cycle 41.64
Total BSC cost per 21 day cycle 167.47
Terminal/Palliative care (weighted one-off cost) 23660.91 Expert panel
BSC: best supportive care
Unit costs and sources for all resource used in the model.
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costs were substituted. No cost was assigned to alopecia.
For FN, the results from the Spanish clinician survey
were not applied since the field survey reported some
impractical assumptions. A flat cost provided by Mayor-
domo, 2009 [18] was therefore applied instead.
Model Inputs: Best Supportive Care Costs
BSC costs were split into two types: 1) BSC costs during
active treatment, post treatment and progression; and 2)
terminal/palliative care costs. In the model, BSC costs
were applied during all three phases (active treatment,
p o s tt r e a t m e n ta n da tp r o g r e s s i o n )b u tt h ec o s tp e r
cycle for BSC was reduced by 50% during the active
treatment phase to reflect the likelihood that less inten-
sive care is required during this period. Applying less
intensive BSC during active treatment is a recognised
practice in Spain and is supported in the Spanish litera-
ture [19].
BSC during active treatment, post treatment and
progression was calculated based on outpatient visits
and home visits. The distribution and frequency of vis-
its to the oncologist, GP, nurse and physiotherapist
were obtained from the opinion-based survey con-
ducted among oncologists in Spain. Resource-use iden-
tified in this survey was multiplied by the unit costs
for services by these healthcare professionals to esti-
mate a cost of BSC. Unit costs for GP visits, nurse vis-
its, physiotherapist visits and oncologist visits were
obtained from the Oblikue database [16]. These costs
per setting values were then weighted according to the
proportion of patients receiving BSC in each setting.
The weighted cost for outpatient and home visits was
calculated at € 241.90 per month, or € 167.47 per 21-
day cycle. For the active treatment phase, this cost was
reduced by 50% to € 83.74 and the reasons for this are
discussed below.
The terminal/palliative care cost consisted of a separate
one-off cost based on the opinion-based survey among
oncologists. Costs for hospital (inpatient), hospice
(inpatient) and nursing home were multiplied by the
average estimated number of days each patient would
spend in each setting to obtain a total palliative care cost.
The cost per day in hospice and the cost per day in nur-
sing home, which were not available from Spain, were
calculated based on the ratio of these costs in the UK
relative to a day in hospital in the UK. The same ratio
was then applied to the cost of a day in hospital in Spain.
A total cost of terminal/palliative care cost was calcu-
lated at € 23,660.91. All patients that entered the term-
inal/palliative care phase were assumed to be extensively
hospitalised, that is, they would each spend some time
in hospital, in hospice or in a nursing home. The impact
of patients spending different proportions of time in
these treatment settings, such as at home, is explored in
the sensitivity analysis.
The model uses a chemotherapy cost of € 2203 for
pemetrexed and € 963 for docetaxel per patient per
cycle based on an assumption of no wastage of the
unused portion in the vials, that is, utilising per mg
costing. In the sensitivity analysis, the impact of
wastage through discarding the remainder of che-
motherapy agents left in the vial was investigated. The
total cost per cycle inclusive of premedication, che-
motherapy, laboratory and administration costs was €
2384 for pemetrexed and € 1144 for docetaxel (Table
5).
Model Inputs: Utility Values
Utility weights assigned to each health state were based
primarily on a societal valuation study of 100 partici-
pants rating health states using the standard gamble
technique [20]. A mixed model analysis was conducted
based on the data collected and values obtained for the
health states Stable, Response and Progression. A decre-
ment in utility was also obtained for each of the AEs,
which are then applied to either the Stable or Response
state, depending on the health state which the patients
currently occupy. Table 6 shows the mean utility values
derived for specific health states.
Table 5 Summary cost of chemotherapy, administration, premedication and laboratory test costs per treatment option
per 21 day cycle
Pemetrexed 500 mg/m
2 (€) Docetaxel 75 mg/m
2 (€)
Chemotherapy costs (based on no wastage) 2202.78 963.31
Administration costs 135.21 135.21
Dexamethasone 1 mg tablets × 30 (Fortecortin®) 2.38 4.75
Folic Acid 400 mcg tablets × 28 (Zolico®) 2.54 -
Vitamin B12 1 mg vial × 8 (Cromatonbic®) 0.13 -
Complete Blood Count includes white cell differential 16.05 16.05
Biochemical Analysis includes renal function and liver function tests 24.78 24.78
Total cost per cycle 2383.87 1144.10
Costs per 21 day cycle for pemetrexed and docetaxel comprising chemotherapy, administration, premedication and laboratory test costs.
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A series of univariate sensitivity analyses were con-
ducted to determine the key drivers of cost-effectiveness
in the model. These one-way sensitivity analyses con-
sider the variation in the incremental cost, incremental
benefit and ICER outcomes when viable ranges of para-
meter values were independently modified. The follow-
ing parameters were varied either according to a fixed
range based on available data (such as 95% Confidence
Interval (CI)) or according to a proportional change
from the base case value (Table 7).
Sensitivity Analysis: Probabilistic
A probabilistic sensitivity analysis was conducted in the
model to take account of the simultaneous effect of second-
order uncertainty relating to parameter values. CIs around
the median statistics for these parameters were determined
based on an assumed distribution of the exponential func-
tion for time-to-event data, and beta distribution for risks
o rr a t e s .U t i l i t yv a l u e sw e r ea l s oa s s u m e dt oh a v eab e t ad i s -
tribution, with their standard errors obtained from 2000
iterations of the mixed model used to obtain the utility
values. These were used to draw repeated samples for the
median overall survival, PFS for non-responders, PFS for
responders, utility values and treatment discontinuation
rates. Each simulated group of samples produced a result.
These simulations were repeated over 1000 iterations to
create a cost-effectiveness plot of likely outcomes, and a
cost-effectiveness acceptability curve (CEAC) to illustrate
the probability of achieving cost-effectiveness given a range
of willingness-to-pay thresholds.
Results
Cost-effectiveness Results
The base case cost-effectiveness analysis was run over a
3-year time-horizon, assuming no wastage, with BSC
provided during treatment, post treatment and at pro-
gression. Patients received a mean of 3.81 pemetrexed
treatment cycles and 3.82 docetaxel treatment cycles out
of a possible maximum of 6 cycles. The comparison of
pemetrexed versus docetaxel resulted in an ICER of €
23967 per QALY and € 17225 per LYG. In this compar-
ison, pemetrexed was found to have a total benefit of
0.52 QALYs compared to 0.42 QALYs for docetaxel. In
terms of LYG, pemetrexed reported 1.03 LYG compared
to 0.89 for docetaxel, an incremental gain of 0.14 life
years. A summary of the results are contained in Tables
8 and 9.
The results indicate that whilst chemotherapy costs
are higher for pemetrexed than docetaxel, the costs of
adverse events are less. Lower AE costs are a result of
less toxicity for pemetrexed compared to docetaxel. In
particular, neutropenia and febrile neutropenia which
incur significant costs in Spain occurred with a notable
difference between pemetrexed and docetaxel. The
pemetrexed arm reported a 4.66% rate of neutropenia,
while docetaxel reported a 41.58% rate; for febrile neu-
tropenia the rates were 2.59% and 15.79%, respectively.
Modelled Survival Curves
Data from the key trial was fitted to the model with an
exponential distribution in order to parameterise the
survival function which assumed a constant hazard rate.
Table 6 Utility values for the health states with/without adverse events
Disease stage Adverse Events within each category Mean utility values
Stable disease No AE 0.65
Grade 3/4 Rash 0.62
Grade 3/4 Alopecia 0.61
Grade 3/4 Fatigue 0.58
Grade 3/4 Nausea & Vomiting 0.61
Grade 3/4 Diarrhoea 0.61
Grade 3/4 Febrile Neutropenia 0.56
Grade 3/4 Neutropenia 0.56
Responding disease No AE 0.67
Grade 3/4 Rash 0.64
Grade 3/4 Alopecia 0.63
Grade 3/4 Fatigue 0.6
Grade 3/4 Nausea & Vomiting 0.62
Grade 3/4 Diarrhoea 0.63
Grade 3/4 Febrile Neutropenia 0.58
Grade 3/4 Neutropenia 0.58
Progressive Disease - 0.47
AE: adverse events; BSC: best supportive care
Mean utility values for each health state, incorporating AE utility decrement.
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showed superior overall survival compared to docetaxel
(Figure 2).
Univariate Sensitivity Analyses
The tornado diagram (Figure 3) shows that the model
is sensitive to one key clinical parameter, overall sur-
vival, which drives the cost-effectiveness. Running the
model using the 95% CI intervals for the survival
hazard ratio for pemetrexed versus docetaxel had the
effect of changing the incremental cost-effectiveness
ratio (ICER) considerably - at the lower limit of the
hazard ratio, indicating a longer overall survival with
pemetrexed, the ICER decreased to € 4891 whilst at
the upper limit of the hazard ratio indicating a
shorter overall survival for pemetrexed, the ICER
increased to € 70768, showing a higher cost but lower
benefit.
Table 7 Univariate sensitivity analysis parameters and ranges
Univariate Sensitivity Parameter Min Max
Discount rate (baseline = 3% for costs, 3% for benefits) 0% 6%
All costs (excluding chemotherapy drugs) varied by ± 25% (baseline = 100%) 75% 125%
Chemotherapy drugs varied by ± 25% (baseline = 100%) 75% 125%
All costs varied by +/- 25% (baseline = 100%) 75% 125%
Per vial costing with 100 mg and 500 mg pemetrexed vials available - -
Mean body surface area (BSA) in m
2 1.6 2
Chemotherapy administration time varied +/- 50% (baseline = 100%) 50% 150%
Hospital days for AE varied +/- 50% (baseline = 100%) 50% 150%
Exclude BSC costs for treated patients once they complete treatment or enter progression - -
Cost of febrile neutropenia varied by +/- 25% (baseline = 100%) € 2483 €4139
Disutility assigned to AEs varied +/- 50% (baseline = 100%) 50% 150%
Assume no disutility assigned to AEs (so only have a cost impact in model) - -
Utility weights assigned to health states varied between upper and lower 95% CI 0.60
stable/response
0.50
with an AE
0.72
stable/response
0.66
with an AE
95% CI for response rate for PEM (base case = 10.78%) 7.25% 15.80%
95% CI for response rate for DOC (base case = 8.81%) 5.59% 13.66%
95% CI for survival hazard ratio for PEM vs. DOC (base case = 0.778) 0.607 0.997
95% CI for progression free survival hazard ratio for PEM vs. DOC (base case = 0.823) 0.664 1.020
Assume weighted terminal/palliative care cost €6927 -
Model time horizon set to 1 year (baseline = 3 years) - -
Setting cost of fatigue to zero --
Duration of treatment (no. of cycles; base case = 6) 4 5
AE: adverse event; BSC: best supportive care; CI: confidential interval; PEM: pemetrexed; DOC: docetaxel
A univariate sensitivity analysis was conducted to test which parameters the cost-effectiveness ratio was sensitive to. Table 7 shows the ranges within which
each parameter was varied.
Table 8 Summary of costs and benefits
Pemetrexed Docetaxel Incremental difference
Total Cost (€) € 34677 € 32343 € 2334
Cost Breakdown
Chemotherapy cost € 8721 € 3997 € 4724
Treatment (admin/premeds) € 691 € 690 € 1
AE cost € 371 € 2891 -€ 2520
BSC cost € 2404 € 1900 € 503
Terminal cost € 22491 € 22865 -€ 374
Total Benefit
QALYs 0.52 0.42 0.10
LYG 1.03 0.89 0.14
AE: adverse event; BSC: best supportive care; QALY: quality-adjusted life year; LYG: life year gained
Table 8 summarises costs and benefits in terms of QALYs and LYG for both pemetrexed and docetaxel. The incremental difference between both treatment arms
is also presented.
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Page 8 of 14The other key drivers of the model are the cost of che-
motherapy drugs, BSC costs during the active treatment
phase and the time horizon of the model. Reducing the
cost of the chemotherapy drugs improves the cost-effec-
tiveness of pemetrexed compared to docetaxel, whilst
excluding BSC costs for patients on treatment reduced
the ICER to € 18799. Setting the time period of analysis
to one year instead of three reduces the ICER to € 16373.
This is due to the treatment costs of AEs being accrued
in the first year alongside chemotherapy. A major cost-
offset is realised by the AE treatment costs, which are
eroded with the consideration of best supportive/pallia-
tive care costs in the ensuing years.
In the model, patients are assumed to spend most of
the time admitted to a hospital or institution during
terminal care. This assumption was tested by using sta-
tistics provided by Gómez-Batiste et al for the propor-
tion of patients dying in different settings, which state
that 42% of patients died at home, 41% in a conven-
tional hospital ward, and 17% in a palliative care centre
[21]. This brought the one-off cost of terminal care
down to € 4600, but the ICER remained similar to the
baseline at approximately € 27000.
Probabilistic Sensitivity Analyses
The results of the PSA correlated the base case results
for each of the patient population groups. The cost-
effectiveness acceptability curves (CEACs) below show
the likelihood of pemetrexed being cost-effective com-
pared to docetaxel when considered across a range of
thresholds for the cost per QALY and per LYG (Figure
4 and Figure 5).
The CEAC plot shows that pemetrexed has a 62%
likelihood of having a cost per QALY below € 30000
and a 77% likelihood of having a cost per LYG below €
30000. These thresholds have been selected based on
Sacristan et al and Ortún et al [22,23].
The cost-effectiveness plot (Figure 6) indicates the
confidence limits that can be placed around the base
case. The plot data from the PSA demonstrates that the
majority of simulations (78%) resulted in additional
costs and benefits for pemetrexed over docetaxel (the
top right quadrant). The probability that pemetrexed
would dominate docetaxel - less costs and additional
benefit - is 13%. There is only a small likelihood (1%)
that pemetrexed would have lower cost and less benefits
than docetaxel, whilst there is an 8% probability that
pemetrexed would have additional cost and less benefit
Table 9 Incremental cost-effectiveness ratio results
ICER Pemetrexed vs Docetaxel
ICER (QALYs) € 23967
ICER (LYG) € 17225
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; LYG:
life year gained
The ICER for pemetrexed versus docetaxel demonstrates that pemetrexed is a
cost-effective treatment compared to docetaxel.
Figure 2 Overall survival curve; model output. Modelled survival curve using data from the JMEI trial demonstrates that pemetrexed has
improved overall survival compared to docetaxel. (PEM: pemetrexed; DOC: docetaxel)
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Page 9 of 14(top left hand quadrant of the plot). This figure also
illustrates that the majority of simulations fall under the
€ 30000 per QALY threshold - 62% of the simulations
fall below the € 30000 per QALY threshold, whilst 77%
fall under € 60000 per QALY and 83% under a € 90000
per QALY threshold.
Discussion
New regimens for the treatment of NSCLC aim to
increase the objective tumour response and survival
rates as well as to reduce toxicity, decrease symptoms
and improve psychological well being for patients. In
inoperable advanced second-line NSCLC, active treat-
ment is well established in Spain and achieves both pal-
liation of symptoms and improvement of QoL in
addition to prolonging survival.
The results of the model show that pemetrexed pro-
duces better outcomes and at an increased cost. At €
23967, the cost per additional QALY for pemetrexed
compared to docetaxel is well within the € 30000
Figure 3 One way sensitivity analysis tornado diagram ICER results. CI: confidence interval; PEM: pemetrexed; DOC: docetaxel; AE: adverse
events; FN: febrile neutropenia; BSC: best supportive care Results from the one way sensitivity analysis demonstrate that the model is primarily
sensitive to the 95% CI for the survival hazard ratio comparing pemetrexed versus docetaxel.
Figure 4 CEAC, cost per QALY pemetrexed compared to docetaxel as the reference. CEAC: cost-effectiveness acceptability curve; QALY:
quality-adjusted life year; ICER: incremental cost-effectiveness ratio. The cost effectiveness acceptability curve demonstrates the likelihoodo f
pemetrexed being cost-effective compared to docetaxel at each ICER threshold value for cost per QALY and cost per LYG.
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Page 10 of 14threshold for QALY discussed by Sacristan and Ortún
[22,23]. The ICERs show that the additional cost incurred
by pemetrexed is justified by the gain in outcomes.
Pemetrexed is associated with a further increase in
overall survival of 0.14 years compared to the current
standard of docetaxel in the predominantly non-squa-
mous histology subgroup, and moreover shows consid-
erable decrease in reported AEs. The avoidance of
treatment-related AEs contributes significantly to the
cost-offset accomplished by using pemetrexed and con-
tributes favourably to the health-related QoL of the
patients undergoing active chemotherapy.
Three randomised phase III trials have consistently
demonstrated the clinical benefit of pemetrexed treat-
ment in patients with predominantly advanced non-
squamous NSCLC [9-11]. These findings resulted in a
specific change to the SmPC indication for pemetrexed
in April 2008 to the second-line treatment of patients
with other than predominantly squamous cell histology
as well as introducing an additional indication for first-
line therapy in combination with cisplatin in this predo-
minantly non-squamous patient group.
Another key consideration contributing to the cost-
effectiveness of pemetrexed is the difference in toxicity
Figure 5 CEAC, cost per LYG pemetrexed compared to docetaxel as the reference. CEAC: cost-effectiveness acceptability curve; QALY:
quality-adjusted life year; ICER: incremental cost-effectiveness ratio
Figure 6 cost-effectiveness plot, cost per QALY. QALY: quality adjusted life year; CE: cost-effectiveness The majority of simulations from the
PSA are in the top right quadrant demonstrating the confidence limits that surround the base case scenario. Threshold values at € 30000, €
60000 and € 90000 have been added to show the number of iterations that fall within each ICER threshold.
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Page 11 of 14profile, especially in severe and expensive AEs such as
neutropenia and FN. The differences in the event rates
for these two AEs are remarkable. For FN pemetrexed
reports a 3% rate as opposed to 16% for docetaxel, and
for neutropenia the difference is even more pronounced
at 5% and 42%, respectively. The impact of these events
is evidenced by the lower ICER when the time horizon
is shortened to a period of one year. At one year, the
key cost differences come from chemotherapy drug
prices and AE costs because best supportive care and
terminal care costs have yet to be accrued in sufficient
amounts. Pemetrexed remaining cost-effective with such
a short time horizon indicates that the cost-difference in
drug prices has been more than made up for with the
difference in AE-related costs.
AE costs were not obtained from published sources in
the literature since such costs in the specific context of
second-line NSCLC patients were not available for the
breadth of AEs included in this model. FN and neutro-
penia costs were particularly important given their sig-
nificant difference in rates between pemetrexed and
docetaxel. The cost of FN was the only one available
from literature [18], based on a retrospective chart
review and adjusted specifically for the context of lung
cancer. About half of the neutropenia patients are trea-
ted as outpatients or day cases, and the medication used
in treating neutropenia must be costed separately. These
include granulocyte colony growth factors (G-CSF),
which have significant cost. The exact proportion of
patients treated with G-CSF in the trial for the non-
squamous population is unavailable; however, the opi-
nion-based survey from which the resource use of AEs
were derived indicates that a majority of clinicians in
Spain would use G-CSF in treating Grade 3/4 neutrope-
nia. The weighted average cost of neutropenia is
approximately two-thirds the cost of an episode of FN,
making it a realistic estimate, given the likelihood that
neutropenia involves less intensive forms of treatment
than FN, distributed among different settings..
BSC was applied at all three stages - during treatment,
post treatment and at progression - though the cost of
BSC during the active treatment phase was reduced by
50% to reflect a reduced need for BSC while the patient
was receiving chemotherapy. This reduction in BSC cost
was included to reflect the assumption that less intensive
BSC is required while patients are on active therapy [19].
Whilst including BSC at all three levels increases the
overall ICER, it is reflective of current practice in Spain,
since most patients receive continuous care throughout
their illness. On average, pemetrexed had a higher BSC
cost than docetaxel. This is attributable to the greater
overall survival of pemetrexed patients, who spend more
time in the Progression state accruing post-treatment
BSC costs. Eliminating BSC during the treatment phase
was examined as a scenario in the sensitivity analysis and
it had the effect of reducing the ICER to € 18799 per
QALY. Both AE and BSC costs were estimated from opi-
nion-based surveys of five Spanish clinicians and hence
may be considered a limitation of the study.
The base case setting reflected current practice in
Spain. It included costs and benefits set at a discount of
3% each and the assumption that left over cytotoxic
agents in vials were reused to minimise wastage as
would be normal practice in most large oncology cen-
tres. A scenario was also run to reflect the possibility of
wastage, as may occur in smaller centres. This had a
small effect of increasing the ICER to € 26741, still
below the accepted threshold.
The univariate sensitivity analysis demonstrated that
the clinical parameter, overall survival, is by far the key
driver of the model. When improved survival rates for
pemetrexed are applied using the lower 95% CIs of the
survival hazard ratio, the ICER is significantly reduced
to € 4891 whilst, conversely, using the upper limits of
the hazard ratio increased the ICER to € 70768. Simi-
larly, adjusting the PFS for pemetrexed using the 95%
CIs of the hazard ratio also had a similar, but less pro-
nounced effect - the impact is greatest at the higher end
of the CI with a shorter PFS for pemetrexed, raising the
ICER to € 32549, just over the € 30000 limit. Both these
clinical parameters have an impact on the rate of death,
which is where the greatest benefit may be identified.
Overall survival directly impacts the calculation of the
risk of death from progression, and the length of PFS
acts to delay patients from entering the Progression
state, which is the only state from which patients may
die, other than febrile neutropenia. To this end, the rate
of neutropenia-related death was also varied to 0% in
the model, but this was found to have a minimal impact.
The model was also sensitive to the cost of che-
motherapy drugs: an increase of 25% in the cost of cyto-
toxics increased the ICER to € 36096. An increase in the
drug acquisition costs acts to increase the overall ICER:
proportional increase implies a larger cost difference of
pemetrexed relative to docetaxel to be compensated for
by savings in such items as reduced toxicity.
The results of the PSA further substantiate the con-
clusion that pemetrexed is a cost-effective alternative to
docetaxel. Of the 1000 simulations run, 92% reported
that pemetrexed will have additional benefit compared
to docetaxel - 78% of the simulations indicated higher
cost and additional benefit as demonstrated in the
north-east quadrant of the cost-effectiveness plot, whilst
a further 13% suggested that pemetrexed would domi-
nate docetaxel with lower costs and additional benefits.
Together, these far outweigh the 8% probability that
pemetrexed has additional costs and fewer benefits than
docetaxel and provide further evidence to endorse the
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group of patients with NSCLC.
The cost-effectiveness acceptability curve demon-
strates that the likelihood of the cost per QALY falling
below € 30000 is 62% and of the cost per LYG is 77%.
These values can provide a degree of confidence in the
probability of pemetrexed being a cost-effective treat-
ment option.
In Spain docetaxel is considered to be the most likely
alternative to pemetrexed and therefore is the main
comparator. Currently, no head-to-head trial data exist
to compare pemetrexed to an intervention other than
docetaxel. An indirect comparison would therefore be
required in order to derive clinical data inputs for other
comparators. This indirect comparison is currently not
feasible against erlotinib and BSC, as no clinical evi-
dence using these two interventions is reported specifi-
cally for the predominantly non-squamous population.
The model does, however, have the capacity to add rele-
vant clinical inputs for these comparators at a future
point in time if either direct comparison data or data to
allow an indirect comparison become available.
A recent cost-utility analysis has however been pub-
lished comparing erlotinib, docetaxel, pemetrexed and
BSC in patients with advanced NSCLC without distin-
guishing histology sub-type who had failed previous che-
motherapy regimens [24]. No difference in efficacy
between pemetrexed and erlotinib was noted - both
reported a QALY gain of 0.24 years and a LYG of 0.77,
but with cost-savings of € 9479 in favour of erlotinib.
This analysis was based on an indirect comparison of the
treatments over a 2 year time horizon using survival
results from three studies: Shepherd 2000, Hanna 2004
and Shepherd 2005 [7,25,26]. This analysis did not differ-
entiate between histology subgroups within the NSCLC
g r o u pa sd a t aw e r eo n l ya v a i l a b l ef o rt h eo v e r a l lN S C L C
population, and it therefore does not account for peme-
trexed’s efficacy benefit seen within the predominantly
non-squamous histology subgroup analysed in this paper.
While no clinical data are reported for a head-to-head
comparison of pemetrexed with BSC, there are other eco-
nomic evaluations that have established the cost-effec-
tiveness of second-line chemotherapy compared to BSC
in the second-line treatment of NSCLC [27,28]. These
studies have found that monotherapy docetaxel is a cost-
effective alternative to BSC. These other studies allow us
to place the current study in the context of other thera-
pies that have been evaluated for their cost-effectiveness.
The model did not take into account dose reductions
or delays in treatment since these estimates are already
accounted for in the phase III trial survival estimates.
The model also assumes the duration of therapy is
linked to AE discontinuation rates and tumour progres-
sion. These data were available from the phase III RCT.
The maximum number of treatment cycles in the base
case was set to 6, which was endorsed by Spanish clini-
cal experts; however, the trial results indicate that the
median number of cycles administered was approxi-
mately four cycles for both treatment arms.
This economic model contains several limitations.
Given the choice of perspective, that of the Spanish
healthcare system, indirect and non-medical costs were
not included in this model. Consideration of a societal
perspective incorporating productivity loss may increase
the burden associated with the disease and the asso-
ciated side-effects of the treatment, thus making the
alleviation of symptoms and reduced toxicity even more
cost-effective. It is unclear how using other methods of
incorporating the societal perspective will impact the
cost-effectiveness of pemetrexed in second-line NSCLC.
Another limitation of this model was the absence of
data to show what effect the third-line therapy choices
may have had on the reported efficacy results. Hanna et
al [25] states that 47% of patients receiving pemetrexed
and 37% of patients receiving docetaxel were ultimately
treated with third-line therapies; the numbers reported
for the non-squamous group are very similar at 48.3%
for those receiving pemetrexed and 37.1% for those
receiving docetaxel [data on file, Eli Lilly JMEI trial
2008]. This indicates that there may have been a possi-
ble confounding factor in the survival advantage attribu-
ted to pemetrexed. However, it should also be noted
that the safety profile of pemetrexed resulted in a
greater proportion of patients whose health status was
good enough at the conclusion of second line therapy to
receive further anti-cancer care.
The choice of an exponential distribution may also be
a limitation of this model. The exponential distribution
assumes a constant hazard rate, which is rarely the case
in real-life survival. There are alternative distributions
that could be used, but it is unlikely that any parame-
terised distribution will perfectly fit the survival curve
output of the trial. Alternative distributions, such as the
Weibull distribution, require additional steps in the
application to an economic model without adding much
value to accuracy in the ultimate result.
Conclusions
In the Spanish setting, pemetrexed for the second-line
treatment of patients with NSCLC other than predomi-
nantly squamous cell histology is indicated as a cost-
effective chemotherapy option compared to the standard
docetaxel, based on its superior overall survival benefit
and toxicity profile.
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